REFERENCES
- Durakovic A. Internal contamination with medically significant radionuclides. In: Conklin JJ, Walker RI, Eds. Military Radiobiology. Orlando: Academic Press, Inc. 1987:241–264.
- Fukuda S. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem. 2005;12(23):2765–2770.
- Ferlic KP, McManaman VL. Nuclear weapons fallout. In: Conklin JJ, Walker RI. Eds. Military Radiobiology. Orlando: Academic Press, Inc. 1987:25–53.
- U.S. Department of Health & Human Services (2010) Managing Internal Contamination (www.remm.nlm.gov/int_contamination.htm#blockingagents_3). 2010.
- Henge-Napoli MH, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. Int J Radiat Biol. 1995;68(4):389–393.
- Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res. 2008;170(4):540–548.
- Durbin PW. Lauriston S. Taylor Lecture: The quest for therapeutic actinide chelators. Health Physics. 2008;95(5):465–492.
- Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004;11(16):2161–2183.
- Fukuda S, Ikeda M, Anzai K, Suzuki M, Katoh A, Kontoghiorghes GJ. Radiation protection by deferiprone in animal models. Hemoglobin. 2006;30(2):201–208.
- Fukuda S, Ikeda M, Nakamura M, Yan X, Xie Y. Efficacy of oral and intraperitoneal administration of CBMIDA for removing uranium in rats after parenteral injections of depleted uranium. Radiat Prot Dosimetry. 2009;133(1):12–19.
- Archimbaud M, Henge-Napoli MH, Lilienbaum D, Desloges M, Montagne C. Application of calixarenes for the decorporation of uranium: present limitations and further trends. Radiat Prot Dosimetry. 1994;53(1-4):327–330.
- Cebrian D, Tapia A, Real A, Morcillo MA. Inositol hexaphosphate: a potential chelating agent for uranium. Radiat Prot Dosimetry. 2007;127(1-4):477–479.
- Leydier A, Lecerclé D, Pellet-Rostaing S, Favre-Reguillon A, Taran F, Lemaire M. Sequestering agent for uranyl chelation: a new family of CAMS ligands. Tetrahedron. 2008;64(28):6662–6669.
- Sawicki M, Siaugue JM, Jacopin C, Moulin C, Bailly T, Burgada R, . Discovery of powerful uranyl ligands from efficient synthesis and screening. Chemistry. 2005;11(12):3689–3697.
- Sawicki M, Lecerclé D, Grillon G, . Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation. Eur J Med Chem. 2008;43(12):2768–2777.
- Henge-Napoli MH, Ansoborlo E, Chazel V, Houpert P, Paquet F, Gourmelon P. Efficacy of ethane-1-hydroxy-1, 1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Int J Radiat Biol. 1999;75(11):1473–1477.
- Liu G, Men P, Kenner GH, Miller SC, Bruenger FW. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics. Nucleosides Nucleotides Nucleic Acids. 2004;23(3):599–611.
- Liu G, Miller SC, Bruenger FW. Efficient synthesis of N-[2-hydroxyethoxy)methyl]-2-alkyl-3-hydroxy-4-pyridinone by a modified Hilbert-Johnson reaction. Synth Commun. 1996;26(14):2681–2686.
- Liu G, Bruenger FW, Miller SC, Arif AM. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(β-D-ribofuranosyl or pyranosyl)-4-pyridinone: Potential iron overload drugs for oral administration. Bioorg Med Chem Lett. 1998;8(21):3077–3080.
- Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel treatment approach for Alzheimer disease. Neurosci Lett. 2009;455(3):187–190.
- Altman SA, Randers L, Rao G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog. 1993;9(6):671–674.
- Fukuda S, Ikeda M, Nakamura M, . The effects of bicarbonate and its combination with chelating agents used for the removal of depleted uranium in rats. Hemoglobin. 2008;32(1-2):191–198.
- Liu G, Miller SC, Bruenger FW. Synthesis of lipophilic 3-hydroxy-2-methyl-4-pyridinone derivatives. Synth Commun. 1995; 25(20):3247–3253.
- Andersen O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004;4(1):11–21.
- Dedeoglu A, Cormier K, Payton S, . Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer’s amyloidogenesis. Exp Gerontol. 2004;39(11-12):1641–1649.